Patents by Inventor Daniele Godelaine
Daniele Godelaine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7998483Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.Type: GrantFiled: July 14, 2009Date of Patent: August 16, 2011Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
-
Patent number: 7785881Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: GrantFiled: January 29, 2008Date of Patent: August 31, 2010Assignee: Ludwig Institute for Cancer ResearchInventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Publication number: 20090274716Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.Type: ApplicationFiled: July 14, 2009Publication date: November 5, 2009Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
-
Patent number: 7563870Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.Type: GrantFiled: June 25, 2004Date of Patent: July 21, 2009Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Bernard Lethé, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
-
Publication number: 20080311652Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: January 29, 2008Publication date: December 18, 2008Inventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 7348007Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: GrantFiled: January 28, 2005Date of Patent: March 25, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Publication number: 20050255553Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: January 28, 2005Publication date: November 17, 2005Applicant: Ludwig Institute of Cancer ResearchInventors: Aline Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Publication number: 20040234541Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.Type: ApplicationFiled: June 25, 2004Publication date: November 25, 2004Applicant: Ludwig Institute for Cancer ResearchInventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
-
Patent number: 6794131Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.Type: GrantFiled: October 18, 1999Date of Patent: September 21, 2004Assignee: Ludwig Institute for Cancer ResearchInventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
-
Patent number: 5811519Abstract: The invention describes the LL-1 tumor specific gene family, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LL-1 gene product.Type: GrantFiled: January 27, 1997Date of Patent: September 22, 1998Assignee: Ludwig Institute for Cancer ResearchInventors: Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur